Group 1 - The core viewpoint of the article highlights the performance of the Hong Kong Stock Connect Innovative Drug ETF (工银, 159217), which experienced a decline of 0.62% on December 1, with a trading volume of 464 million yuan [1] - The fund's total shares decreased by 2 million, bringing the latest total to 3.865 billion shares, while the shares have increased by 17.3 million over the past 20 trading days [1] - The latest net asset value of the fund is calculated to be 5.56 billion yuan [1] Group 2 - The performance benchmark for the Hong Kong Stock Connect Innovative Drug ETF is the adjusted return rate of the Guotai Junan Hong Kong Stock Connect Innovative Drug Index [1] - The fund is managed by ICBC Credit Suisse Asset Management Company, with fund managers Liu Weilin and Jiao Wendong [1] - Since its establishment on March 26, 2025, the fund has achieved a return of 43.85%, with a monthly return of 2.20% [1]
12月1日港股通创新药ETF工银（159217）份额减少200.00万份
Xin Lang Cai Jing·2025-12-02 01:12